Vertical transmission and humoral immune response following maternal infection with SARS-CoV-2: a prospective multicenter cohort study.
Antibodies
COVID-19
Neonates
Pregnancy
SARS-CoV-2
Journal
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
ISSN: 1469-0691
Titre abrégé: Clin Microbiol Infect
Pays: England
ID NLM: 9516420
Informations de publication
Date de publication:
Sep 2022
Sep 2022
Historique:
received:
28
11
2021
revised:
27
03
2022
accepted:
04
04
2022
pubmed:
16
4
2022
medline:
20
9
2022
entrez:
15
4
2022
Statut:
ppublish
Résumé
To explore maternal humoral immune responses to SARS-CoV-2 infection and the rate of vertical transmission. A prospective cohort study was conducted at two university-affiliated medical centers in Israel. Women positive for SARS-CoV-2 reverse-transcription-polymerase-chain-reaction (RT-PCR) test during pregnancy were enrolled just prior to delivery. Levels of anti-SARS-CoV-2 spike-IgM, spike IgG, and nucleocapsid IgG were tested in maternal and cord blood at delivery, and neonatal nasopharyngeal swabs were subjected to PCR testing. The primary endpoint was the rate of vertical transmission, defined as either positive neonatal IgM or positive neonatal PCR. Among 72 women, 36 (50%), 39 (54%) and 30 (42%) were positive for anti-spike-IgM, anti-spike-IgG, and anti-nucleocapsid-IgG, respectively. Among 36 neonates in which nasopharyngeal swabs were taken, one neonate (3%, 95% confidence interval 0.1-15%) had a positive PCR result. IgM was not detected in cord blood. Seven neonates had positive IgG antibodies while their mothers were seronegative for the same IgG. Anti-nucleocapsid-IgG and anti-spike-IgG were detected in 25/30 (83%) and in 33/39 (85%) of neonates of seropositive mothers, respectively. According to the serology test results during delivery with respect to the time of SARS-CoV-2 infection, the highest rate of positive maternal serology tests was 8 to 12 weeks post-infection (89% anti-spike IgG, 78% anti-spike IgM, and 67% anti-nucleocapsid IgG). Thereafter, the rate of positive serology tests declined gradually; at 20 weeks post-infection, only anti-spike IgG was detected in 33 to 50%. The rate of vertical transmission of SARS-CoV-2 was at least 3% (95% confidence interval 0.1-15%). Vaccination should be considered no later than 3 months post-infection in pregnant women due to a decline in antibody levels.
Identifiants
pubmed: 35427778
pii: S1198-743X(22)00204-X
doi: 10.1016/j.cmi.2022.04.001
pmc: PMC9005357
pii:
doi:
Substances chimiques
Antibodies, Viral
0
Immunoglobulin G
0
Immunoglobulin M
0
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1258-1262Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2022 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
Références
Am J Reprod Immunol. 2015 Mar;73(3):251-62
pubmed: 25091957
Am J Obstet Gynecol. 2020 Jun;222(6):521-531
pubmed: 32217113
Clin Infect Dis. 2020 Nov 19;71(16):2035-2041
pubmed: 32249918
N Engl J Med. 2022 Mar 31;386(13):1221-1229
pubmed: 35172072
J Pers Med. 2021 May 28;11(6):
pubmed: 34071251
Prenat Diagn. 2020 Dec;40(13):1759-1761
pubmed: 32304114
Am J Obstet Gynecol. 2020 Aug;223(2):275-278
pubmed: 32405074
Ann Transl Med. 2020 Feb;8(3):47
pubmed: 32154287
JAMA. 2020 Jun 2;323(21):2198-2200
pubmed: 32352491
J Glob Antimicrob Resist. 2020 Sep;22:754-755
pubmed: 32623000
Clin Infect Dis. 2021 Mar 1;72(5):862-864
pubmed: 32182347
Am J Obstet Gynecol. 2021 Jan;224(1):35-53.e3
pubmed: 32739398
Clin Microbiol Infect. 2021 Sep;27(9):1349.e1-1349.e6
pubmed: 33975009
Am J Obstet Gynecol MFM. 2020 Aug;2(3):100133
pubmed: 32391518
BJOG. 2020 Aug;127(9):1116-1121
pubmed: 32339382
Am J Obstet Gynecol MFM. 2020 May;2(2):100118
pubmed: 32292903
Lancet. 2020 Mar 7;395(10226):809-815
pubmed: 32151335
JAMA. 2020 May 12;323(18):1846-1848
pubmed: 32215581
Am J Perinatol. 2020 Jun;37(8):861-865
pubmed: 32305046
JAMA. 2020 May 12;323(18):1848-1849
pubmed: 32215589
Front Pediatr. 2020 Mar 16;8:104
pubmed: 32266184
Sci Immunol. 2017 Sep 1;2(15):
pubmed: 28864494